United States Drug Patent 8,580,830: Claim Scope, Validity, Orange Book Status and Ondansetron Film Patent Landscape

US Patent No. 8,580,830 protects a narrow ondansetron dosage form rather than ondansetron generally. The independent claims require a non-mucoadhesive, saliva-disintegrating oral film with defined dose, pharmacokinetic, bioavailability and gastrointestinal-delivery characteristics. The principal commercial relevance is the ondansetron oral soluble film product Zuplenz, approved by FDA under NDA 022524.[1]

The patent’s strongest enforcement position is against films that combine ondansetron, rapid buccal disintegration, limited oral-mucosal absorption and the claimed 4 mg or 8 mg dose. Conventional ondansetron tablets, orally disintegrating tablets, injectables, conventional oral solutions and films that do not satisfy the pharmacokinetic or delivery limitations fall outside the literal scope of the claims.

What patent is US 8,580,830 and what product does it protect?

US 8,580,830 is directed to non-mucoadhesive orally disintegrating films containing ondansetron. The claimed technology is designed to dissolve quickly in the mouth while directing most of the active ingredient to the gastrointestinal tract rather than permitting substantial absorption through the buccal or sublingual mucosa.

Item	Analysis
Patent	US 8,580,830
Active ingredient	Ondansetron or a pharmaceutically acceptable salt
Dosage form	Non-mucoadhesive orally disintegrating film
Disintegration requirement	About 60 seconds or less upon contact with saliva
Principal doses	About 4 mg to 24 mg; dependent claims focus on 4 mg and 8 mg
Key pharmacokinetics	Tmax of about 1.0 to 2.5 hours
Bioavailability	About 45% to 75%
Delivery objective	More than 60% of ondansetron delivered to the gastrointestinal tract
Commercial product association	Zuplenz oral soluble film
FDA product status	Approved ondansetron oral soluble film under NDA 022524
Patent type	Small-molecule formulation and dosage-form patent

The claims do not cover every ondansetron film. They require a specific combination of formulation architecture and performance parameters.

What does independent claim 1 require?

Claim 1 has multiple cumulative limitations. A potentially infringing product must satisfy all material elements, subject to claim construction and any prosecution-history limitations.

Dosage-form limitations

The product must be:

A film.
Non-mucoadhesive.
Orally disintegrating.
Capable of disintegrating in the buccal cavity upon contact with saliva within about 60 seconds.
Formulated with a hydrophilic binder and a water-soluble diluent.

A film that intentionally adheres to the mucosa may avoid the non-mucoadhesive limitation, although the practical enforceability of that distinction would depend on the product’s actual formulation and in-mouth behavior.

Active-ingredient limitations

The film must contain:

Ondansetron or a pharmaceutically acceptable salt;
About 4 mg to 24 mg of ondansetron or its salt; and
About 0.05% to 50% ondansetron by total film weight.

The weight-percentage limitation is broad. It can capture both relatively low-load films and formulations with a high drug fraction. The dose limitation is narrower in practice because commercial antiemetic products generally use 4 mg or 8 mg doses.

Pharmacokinetic limitations

Claim 1 requires:

A Tmax of about 1.0 to 2.5 hours; and
Absolute bioavailability of about 45% to 75%.

These limitations create significant litigation and design-around issues. They are not defined solely by ingredients. A competitor may use a similar composition but argue that its clinical or pharmacokinetic profile falls outside the claimed ranges.

The claim does not state the precise study population, dosing conditions, analytical method, reference formulation or statistical treatment for determining Tmax and absolute bioavailability. Those issues could become important in an infringement dispute. Courts generally construe pharmacokinetic limitations according to the patent specification, prosecution history and accepted scientific methodology.

Oral-mucosal absorption limitation

Claim 1 also requires a means for retarding oral-mucosal absorption that delivers more than 60% of ondansetron to the gastrointestinal tract after the film is placed on the tongue, disintegrated and swallowed.

The listed mechanisms include:

Ion-exchange resins;
pH-adjusting agents;
Cyclodextrins;
Acrylate polymers; and
Ondansetron in free-base form.

The ion-exchange-resin subcategory is described as binding ondansetron and preventing its ionization and dissolution during film disintegration. The claim lists polymers and copolymers involving acrylic acid, methacrylic acid, sulfonated styrene, sulfonated divinylbenzene, dextrans and ionically modified silica gel.

This limitation is central to the patent. The invention is not merely a fast-dissolving film. It is a fast-dissolving film intended to reduce buccal absorption and promote swallowing.

How do claims 2 through 5 narrow the patent?

Claims 2 through 5 create a nested performance hierarchy:

Claim	Required gastrointestinal delivery
Claim 1	Greater than 60%
Claim 2	Greater than 70%
Claim 3	Greater than 80%
Claim 4	Greater than 90%
Claim 5	Greater than 95%

Claims 2 through 5 depend on claim 1. A product meeting claim 5 necessarily meets the greater-than-60%, greater-than-70%, greater-than-80% and greater-than-90% thresholds, assuming the same test method applies.

The higher-threshold claims are narrower but may have greater evidentiary value against a product whose testing demonstrates very high gastrointestinal delivery. Claims 4 and 5 may also be more vulnerable to reproducibility disputes because small variations in saliva volume, residence time, swallowing behavior and analytical recovery could affect the result.

What does claim 6 protect?

Claim 6 specifies Form B ondansetron. This is a solid-state limitation directed to a particular polymorphic form.

A product using a different polymorph, amorphous ondansetron, a salt, or a solvate may avoid claim 6 but could still infringe claim 1 or claim 12 if the broader limitations are met. Solid-form claims are often tested through powder X-ray diffraction, thermal analysis, infrared spectroscopy, solid-state NMR or other validated analytical methods.

The specification and file history would control the precise structural definition of “Form B.” A label or supplier specification alone may not resolve infringement if conversion between polymorphs occurs during manufacturing or storage.

What does claim 7 protect?

Claim 7 narrows the product to either 4 mg or 8 mg of ondansetron. These are the principal commercial strengths associated with ondansetron oral films.

A 4 mg or 8 mg product remains subject to all limitations of claim 1, including:

Non-mucoadhesive film construction;
Hydrophilic binder;
Water-soluble diluent;
Rapid disintegration;
Tmax;
Absolute bioavailability;
Oral-mucosal absorption retardation; and
Greater-than-60% gastrointestinal delivery.

A 4 mg or 8 mg film that lacks the claimed delivery mechanism or pharmacokinetic profile would not necessarily infringe claim 7.

What do claims 8 through 10 protect?

Claim 8: physical film dimensions

Claim 8 requires a single-layer homogeneous film with:

Weight of about 40 to 120 mg;
Thickness of about 10 to 200 microns; and
Surface area below 7 cm².

These limitations target a thin, compact, single-layer dosage form. A multilayer film, a thicker laminate, or a film exceeding the surface-area limit may avoid claim 8 while remaining exposed under broader claims.

“Homogeneous” may create a technical dispute. A film can be visually uniform but still have microscopic drug-concentration variation. The patent specification and manufacturing disclosure would be important in determining whether the term refers to visual appearance, composition, layer structure or content uniformity.

Claims 9 and 10: specific formulation

Claim 9 identifies a formulation containing:

Ondansetron;
Polyvinyl alcohol;
Polyethylene glycol;
Anhydrous glycerol;
Rice starch;
Acesulfame potassium;
Titanium dioxide;
Menthol; and
Polysorbate.

Claim 10 provides a specific 8 mg formulation:

Component	Amount
Ondansetron	8.0 mg
Polyvinyl alcohol	22.0 mg
Polyethylene glycol	6.0 mg
Anhydrous glycerol	2.0 mg
Rice starch	10.0 mg
Acesulfame potassium	0.2 mg
Titanium dioxide	0.3 mg
Menthol	1.0 mg
Polysorbate	1.0 mg

The formulation totals approximately 50.5 mg before accounting for any salt-form conversion, residual water, manufacturing variation or additional excipients. Claim 10 is materially narrower than claim 1 and may be avoided by replacing one listed excipient or materially changing the amount, subject to the doctrine of equivalents.

The apparent typographical error in the supplied text, “0.3 tug titanium dioxide,” should be treated as 0.3 mg if that is how the issued patent presents the amount. The issued patent, certified copy and prosecution record control.

What does claim 11 protect?

Claim 11 is a medical-use claim for treatment or prevention of emesis. It narrows the film’s use to an antiemetic indication.

Because ondansetron is already known for nausea and vomiting, the commercial value of claim 11 depends on the film dosage form and the non-mucoadhesive delivery technology, not on the general discovery that ondansetron treats emesis.

How does claim 12 differ from claim 1?

Claim 12 is an independent claim. It narrows several features while preserving the core delivery concept.

Feature	Claim 1	Claim 12
Ondansetron form	Ondansetron or salt	Free base
Dose	About 4 to 24 mg	About 4 or about 8 mg
Dose percentage	0.05% to 50%	0.05% to 50%
Tmax	1.0 to 2.5 hours	1.0 to 2.5 hours
Absolute bioavailability	45% to 75%	45% to 75%
Oral-mucosal retardation	Required	Required
GI delivery	Greater than 60%	Greater than 60%

Claim 12 may be commercially significant because the free-base limitation aligns with an approach that can reduce ionization and oral-mucosal penetration. A product using ondansetron hydrochloride rather than the free base may avoid claim 12 but remain potentially relevant to claim 1.

What is the likely claim-construction issue for “means for retarding absorption”?

The phrase “means for retarding absorption” is likely to raise a means-plus-function issue under 35 U.S.C. §112(f). If treated as a means-plus-function limitation, the claim may be limited to the corresponding structures disclosed in the specification and their statutory equivalents rather than every conceivable absorption-retarding technology.[2]

The patent identifies several structures and mechanisms. The main legal questions would include:

Whether the claim invokes §112(f);
What corresponding structures the specification discloses;
Whether the listed resin classes are exhaustive;
Whether a competitor’s excipient performs the identical function in substantially the same way;
Whether “greater than 60%” is a structural requirement, a functional result or both; and
Whether the gastrointestinal-delivery test is sufficiently definite and reproducible.

A competitor using a novel polymer that slows dissolution but does not bind ondansetron, alter pH or use a cyclodextrin would have a stronger noninfringement position than a competitor using an equivalent ion-exchange resin under a different commercial name.

What is the Orange Book status of US 8,580,830?

Zuplenz was approved by FDA as an ondansetron oral soluble film under NDA 022524.[1] FDA’s Orange Book is the controlling source for listed patents, use codes, expiration dates and any patent delisting or expiration updates.[3]

The patent’s practical Orange Book relevance depends on:

Whether US 8,580,830 is listed against NDA 022524;
The use code associated with the listing;
The listed expiration date;
Whether FDA granted pediatric exclusivity;
Whether the NDA holder amended or removed the listing; and
Whether an approved ANDA cites the NDA and files a Paragraph IV certification.

The supplied claim text alone does not establish the current Orange Book listing status or the operative expiration date. The patent’s enforceable term must be checked against the USPTO patent record, any patent-term adjustment and the current Orange Book entry.

When does US 8,580,830 lose exclusivity?

The patent loses patent exclusivity at the end of its enforceable term, subject to patent-term adjustment, terminal disclaimers, disclaimers of claims and any applicable pediatric extension. Regulatory exclusivity is separate.

For Zuplenz, the relevant regulatory pathway is an NDA for a small-molecule drug. It is not a biologic, so biosimilar exclusivity rules do not apply. A generic applicant would generally proceed through an ANDA rather than a 351(k) biosimilar application.[4]

A definitive launch date requires four separate determinations:

The patent’s statutory expiration date;
Any patent-term adjustment;
Any applicable pediatric exclusivity;
The status of FDA-listed patents and exclusivity on the proposed launch date.

A patent expiration date shown in a commercial database should not replace the USPTO and Orange Book records for transaction or litigation decisions.

What Paragraph IV challenges and generic-entry risks exist?

An ANDA applicant seeking approval before patent expiry could submit a Paragraph IV certification alleging that the listed patent is invalid, unenforceable or not infringed.[5] The NDA holder could then bring an infringement action within 45 days, triggering the statutory 30-month stay of ANDA approval, subject to statutory exceptions and court developments.[6]

For this patent, likely Paragraph IV theories include:

Noninfringement

A generic applicant could design around one or more of the following:

Use a mucoadhesive rather than non-mucoadhesive film;
Use a dosage form that disintegrates outside the claimed time;
Use a salt or polymorph outside a narrower claim;
Avoid the claimed 4 mg or 8 mg dose;
Use a formulation with different Tmax or bioavailability;
Demonstrate less than the required gastrointestinal delivery;
Omit the claimed absorption-retarding mechanism; or
Use a multilayer or physically different film outside claim 8.

Invalidity

Potential validity issues could involve:

Anticipation by earlier ondansetron film disclosures;
Obviousness over ondansetron oral dosage forms combined with fast-dissolving film technology;
Lack of written description for the full breadth of resin, pH, cyclodextrin and acrylate alternatives;
Enablement of every claimed pharmacokinetic and delivery combination;
Indefiniteness of “about,” “greater than,” “homogeneous,” or the testing conditions; and
Lack of objective boundaries for the bioavailability and Tmax limitations.

The strongest invalidity defense would require prior-art evidence directed to the complete combination, not merely separate disclosures of ondansetron, oral films and rapid disintegration.

What formulation patents and method-of-use patents compete with US 8,580,830?

The relevant landscape has four layers:

Patent layer	Typical protected subject matter	Relevance to 8,580,830
Active-ingredient patents	Ondansetron composition or salt	Likely expired or historically important
Solid-form patents	Polymorphs such as Form B	Potentially relevant to claim 6
Film-formulation patents	Polymer matrix, plasticizer, casting and drying process	Main adjacent estate
Method-of-use patents	Treatment or prevention of emesis	Narrower commercial protection

The patent is strongest where a competitor’s film follows the same product architecture: a thin, rapidly disintegrating, non-mucoadhesive film using a hydrophilic polymer and a mechanism that promotes swallowing rather than buccal absorption.

It is weaker against:

Buccal or sublingual films intended for transmucosal delivery;
Conventional orally disintegrating tablets;
Liquid ondansetron products;
Films using different active ingredients;
Films with materially different pharmacokinetics; and
Products that do not use the disclosed absorption-retarding mechanisms.

Does biosimilar risk apply to ondansetron?

No. Ondansetron is a chemically synthesized small molecule. Biosimilar litigation under the Biologics Price Competition and Innovation Act is not the relevant pathway. Competitive entry would occur through generic-drug approval, typically using an ANDA and a Paragraph I, II, III or IV patent certification depending on the patent and proposed launch date.[4]

The main regulatory risk is therefore generic film entry, not biosimilar substitution.

Which companies are relevant to the competitive landscape?

The principal commercial entity associated with the product is Aquestive Therapeutics, formerly operating through MonoSol-related corporate structures. The competitive field includes:

Generic pharmaceutical companies developing ondansetron oral films;
Manufacturers of ondansetron orally disintegrating tablets;
Suppliers of oral-film manufacturing technology;
Companies developing buccal and sublingual antiemetic products; and
Contract manufacturers with solvent-casting or hot-melt oral-film capability.

The most material competitive distinction is delivery route. A product designed for gastrointestinal delivery after rapid oral disintegration is closer to the claimed technology than a transmucosal product designed for direct systemic absorption through the mouth.

What manufacturing and intellectual-property barriers matter?

The patent’s manufacturing relevance extends beyond the final ingredient list. A competing manufacturer must control:

Uniform drug distribution in a thin film;
Film tensile strength and flexibility;
Dose content uniformity;
Residual solvent or moisture;
Polymorph stability;
Rapid saliva disintegration;
Non-mucoadhesive behavior;
Packaging against humidity;
Scale-up of casting and drying; and
Reproducible gastrointestinal-delivery performance.

Even if a competitor avoids literal infringement, process know-how may create a commercial barrier. Thin-film manufacturing requires different equipment and quality controls from tablet compression. However, manufacturing complexity does not independently establish patent infringement.

How strong is the patent estate?

The patent is commercially meaningful but claim scope is narrower than the product concept suggests.

Strength factor	Assessment
Product-specific relevance	High for an ondansetron oral soluble film matching the claimed performance
Breadth against conventional ondansetron products	Low
Breadth against all oral films	Low
Formulation specificity	Moderate to high
Dependence on clinical testing	High
Design-around potential	Moderate
Invalidity exposure	Dependent on prior art and specification support
Biosimilar exposure	None
Generic-entry exposure	Material after patent and regulatory barriers lapse

The principal weakness is the number of functional and pharmacokinetic limitations. Those limitations can narrow infringement but also create validity, definiteness and proof issues. The principal strength is the combination of structural, dosage-form and performance requirements, which may make a direct copy easier to identify.

What licensing deals and settlements affect the patent?

The supplied materials do not establish a definitive license, covenant not to sue, Paragraph IV settlement, authorized-generic arrangement or litigation settlement involving US 8,580,830. Such agreements may be confidential or reflected only indirectly in FDA approval records, court dockets, SEC filings or Orange Book changes.

A transaction review should treat the following as controlling sources:

FDA Orange Book listing history;
FDA approval letters and patent certifications;
USPTO assignment and maintenance records;
PACER litigation dockets;
SEC filings by the NDA holder or licensees; and
Any public settlement or license agreement.

Key Takeaways

US 8,580,830 protects a specific ondansetron oral-film platform, not ondansetron generally.
The core combination is a non-mucoadhesive, saliva-disintegrating film with a hydrophilic binder, water-soluble diluent, defined dose, defined pharmacokinetics and reduced oral-mucosal absorption.
Claims 2 through 5 progressively increase the required gastrointestinal delivery from more than 70% to more than 95%.
Claim 6 targets Form B ondansetron, while claims 7 through 10 focus on commercial doses, dimensions and formulation ingredients.
Claim 12 independently targets 4 mg or 8 mg ondansetron free-base films.
The most credible design-around routes involve changing the ondansetron form, absorption mechanism, film architecture, dose, pharmacokinetic profile or gastrointestinal-delivery result.
Ondansetron is a small molecule, so biosimilar risk does not apply. Generic ANDA and Paragraph IV risk is the relevant pathway.
Current patent expiry, Orange Book listing, regulatory exclusivity and settlement status must be determined from the operative USPTO, FDA and court records rather than the claim text alone.

FAQs

Can a conventional ondansetron orally disintegrating tablet infringe US 8,580,830?

Generally, no, because the claims require a film. A tablet would also need to satisfy the film-specific structural and performance limitations, which would be difficult on the supplied claim language.

Does using ondansetron hydrochloride avoid claim 12?

Potentially, because claim 12 requires ondansetron in free-base form. It would not automatically avoid claim 1, which covers ondansetron and pharmaceutically acceptable salts.

Can a multilayer ondansetron film avoid the patent?

It may avoid claim 8, which requires a single-layer homogeneous film. It may still face claims 1 through 7 or claim 12 if the multilayer product meets their independent limitations.

Is a film infringing if it disintegrates in less than 60 seconds but delivers less than 60% of ondansetron to the gastrointestinal tract?

On the supplied claim language, likely not under claim 1 because greater-than-60% gastrointestinal delivery is a required limitation. The product could still require analysis under other patent claims or the doctrine of equivalents.

Does a different polymer automatically avoid the absorption-retarding limitation?

No. The answer depends on whether the polymer falls within the expressly listed categories, performs the claimed function through a disclosed mechanism, or is equivalent to a disclosed structure under the applicable claim construction.

References

U.S. Food and Drug Administration. (2010). Zuplenz (ondansetron hydrochloride) oral soluble film: Prescribing information. NDA 022524.
United States Congress. (2011). 35 U.S.C. § 112: Specification.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certifications.
United States Congress. (2011). 21 U.S.C. § 355(j)(2)(A)(vii)(IV): Paragraph IV certification.
United States Congress. (2011). 21 U.S.C. § 355(j)(5)(B)(iii): 30-month stay of approval.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Aquestive	ZUPLENZ	ondansetron	FILM;ORAL	022524-001	Jul 2, 2010		DISCN	Yes	No	8,580,830	⤷ Start Trial	Y				⤷ Start Trial
Aquestive	ZUPLENZ	ondansetron	FILM;ORAL	022524-002	Jul 2, 2010		DISCN	Yes	No	8,580,830	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

PCT Information
PCT Filed	October 02, 2007	PCT Application Number:	PCT/EP2007/008579
PCT Publication Date:	April 10, 2008	PCT Publication Number:	WO2008/040534

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007304425	⤷ Start Trial
Brazil	PI0719840	⤷ Start Trial
Canada	2664986	⤷ Start Trial
China	101626756	⤷ Start Trial
China	105168186	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,580,830